PTHS — Pelthos Therapeutics Inc.

—
NYSE · Health Care · Biotechnology · CIK 1919246 ·
Last close
$6.84
Market Cap
$26.89M
52W High
$32.51
52W Low
$6.76
ADV30
64,295
Next earnings
2026-11-12
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 15,395,000 10,287,000 -9,693,000 -7,895,000 128,817,000 17,690,000 135,003,000
Jun 2026 15,603,000 2,774,000 -17,323,000 -23,417,000 137,356,000 24,192,000 138,857,000
Mar 2026 10,906,000 5,594,000 -13,088,000 -25,073,000 145,378,000 31,976,000 110,276,000
Dec 2025 9,389,000 4,999,000 -12,003,000 -21,664,000 130,397,000 17,973,000 91,516,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-32,206,000
Investing CF
$2,505,000
Financing CF
$44,369,000
CapEx
$-256,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-23.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-121,179,000
Inventory
$21,471,000
Receivables
$13,413,000
ST Investments
—
EBIT TTM
$-76,646,000
Pretax Income TTM
$-84,971,000
Interest Exp TTM
$8,325,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$43,304,000
EBITDA
—
Free Cash Flow
$-36,573,780
Enterprise Value
$77,400,808
Total Cash
$24,192,000
Total Debt
$73,109,000
Shares Out
3,930,709
Trailing EPS
$-23.86
Book Value
$-0.40
ROE
-333.8%
ROA
-50.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 16,795,000 -32,430,000 -43,319,000 130,397,000 91,516,000 38,881,000 -22,590,000
Dec 2024 0 -7,571,000 -7,955,000 1,369,000 4,083,000 -2,714,000 -5,792,000
Dec 2023 0 -6,862,284 -7,380,793 96,391 6,540,943 -6,444,552 -981,031
Dec 2022 0 -2,318,159 -2,458,589 55,074 3,761,611 -3,706,537 -1,567,149

TTM Snapshot

Revenues TTM
$43,304,000
NetIncome TTM
$-71,557,450
OpCashFlow TTM
—
Assets (Latest)
$137,356,000
Forward EPS
$-6.56

Peers — same industry

TickerNameMarket CapLastDaily %
LONA LeonaBio, Inc. $26.00M $2.76 —
SAEN Genenta Science S.p.A. $27.82M $0.58 —
EVAX Evaxion A/S $25.08M $2.78 —
INMB Inmune Bio, Inc. $29.72M $0.96 —
MGX Metagenomi Therapeutics, Inc. $23.86M $0.63 —

News headlines (Yahoo Finance, 1h cache)

Pelthos Therapeutics (PTHS) Stock Sees Fair Value Cut As Analysts Rework Launch And Merger Risks
2026-11-16 15:15 · Yahoo
Pelthos Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-13 01:35 · Yahoo
Pelthos (PTHS) Q3 2026 Earnings Call Transcript
2026-11-13 00:29 · Yahoo
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 12:25 · Yahoo
Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:00 · Yahoo
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-11-04 21:05 · Yahoo
Pelthos and Castle Creek plan merger to target skin diseases
2026-11-02 10:55 · Yahoo
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
2026-10-30 13:09 · Yahoo
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
2026-10-06 12:00 · Yahoo
Pelthos (PTHS) Q2 2026 Earnings Call Transcript
2026-08-20 13:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.